Ah … yes nice point.
There is a little bit of chicken and egg when a 3 arm trial is created; comprising two intervention arms and placebo. Whether the context is driving the design or the scientific question.
But from the perspective of the participant they will skip the nuance about the difference between the two investigation arms and go straight to bit where they read 2 chances in 3 of receiving the active - rexlemestrocel-L. Eg … from the PIS from one of the centres participating in the study
“Two of the groups will receive the investigational product (rexlemestrocel-L, either alone or with hyaluronic acid) and one group will receive placebo (saline). A placebo (saline) looks like the study drug, but does not contain any active ingredient(s).
You have an equal chance of being assigned to any one of the three groups.
You have a 2 out of 3 chance of being assigned to one of the two groups that will receive the investigational product, rexlemestrocel-L.
You have a 1 out of 3 chance of being randomly assigned to the placebo (saline alone) group. “
http://proslc.com/wp-content/uploads/2016/06/URRENT-consent-mesoblast-study.5.4.16.pdf
But it’s a good pick up you made … I’ll leave my post there (not moderate it) as everyone can read your good counter point. And at the least people might welcome a temporary distraction from the usual finance discussion on this forum.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment, page-147
-
- There are more pages in this discussion • 126 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B |
Open | High | Low | Value | Volume |
$1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 32999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8683 | 1.155 |
7 | 295447 | 1.150 |
3 | 70786 | 1.145 |
6 | 196386 | 1.140 |
3 | 75486 | 1.135 |
Price($) | Vol. | No. |
---|---|---|
1.165 | 32999 | 1 |
1.170 | 62618 | 6 |
1.175 | 48590 | 3 |
1.180 | 79079 | 4 |
1.185 | 17090 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online